The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gut microbiota perturbations in response to SARS-CoV-2 and survival outcomes in patients with cancer.
 
Alba Santiago Badenas
No Relationships to Disclose
 
Nuria Moragas Garcia
No Relationships to Disclose
 
Fiorella Ruiz-Pace
No Relationships to Disclose
 
Mireia Obon Santacana
No Relationships to Disclose
 
Iosune Baraibar
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - Amgen; Merck; SERVIER
 
Maria Vieito Villar
Consulting or Advisory Role - BMS; myTomorrows; SERVIER
Speakers' Bureau - Novocure
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche; Roche/Genentech (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - BMS GmbH & Co. KG (Inst); Debiopharm Group (Inst); HUTCHMED (Inst); Incyte (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst)
 
Ariadna Garcia
No Relationships to Disclose
 
Laura Boleda Monferrer
No Relationships to Disclose
 
Mafalda Oliveira
Honoraria - AstraZeneca; Curio Science; Eisai; Gilead Sciences; i-One; Libbs; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD; Pfizer; ProteinQure; Relay Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Immutep (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Roche
(OPTIONAL) Uncompensated Relationships - President elected, SOLTI Cancer Research Group
 
Andri Papakonstantinou
No Relationships to Disclose
 
Nuria Mulet Margalef
Expert Testimony - Amgen
Travel, Accommodations, Expenses - Amgen; Merck; MSD
 
Paula Gubern Prieto
No Relationships to Disclose
 
Elisabet Guino
No Relationships to Disclose
 
Stefania Napoli
No Relationships to Disclose
 
Juan Aguilar-Company
No Relationships to Disclose
 
Cristina Saura Manich
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Exeter Pharmaceuticals; Pfizer; Phillips Health Works; Pierre Fabre; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; F. Hoffmann LaRoche; Gilead Sciences; Lilly; MediTech; Menarini; Menarini; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Debiopharm Group (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Janssen-Cilag SA (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merck Health KGAA, Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); SERVIER (Inst); Spanish Association Against Cancer Scientific Foundation and Cancer Research UK (Inst); Taiho Pharma USA Inc, (Inst)
Expert Testimony - AX`s consulting SARL; Boehringer Ingelheim; Bristol-Myers Squibb/Sanofi; Genentech; InnoUp; Merck Sharp and Dohme Spain; Novartis; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Puma Biotechnology; Roche; Seagen
 
Elena Garralda
Employment - NEXT Oncology (IOB)
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; Amgen; Anaveon; Astex Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo/Lilly; Ellipses Pharma; Genmab; Gilead Sciences; Greywolf; Hengrui Therapeutics; Incyte; Janssen; Marengo Therapeutics; Medpace; Pfizer; Roche; Sanofi; Seagen; Skypta; Sotio
Speakers' Bureau - AEFI; Alcura; Aran; AstraZeneca; CDDF; Doctaforum; ESMO; European School Oncology (ESO); Fundación ECO; Fundación SEOM; Horizon CME; Karger Publishers; Medscape; MeetingPharma; MSD; Novartis; PPD Global; Roche; Seagen; Springer Nature; Tactics; The Ricky Rubio Fundation
Research Funding - Anaveon; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Elena Elez
Honoraria - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Speakers' Bureau - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson & Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Agenus (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech, Therapeutics, S.L. (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim de España S.A. (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Enterome BioScience SA (Inst); Exelixis (Inst); Genentech (Inst); Gercor (Inst); GlaxoSmithKline (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); NuCana plc. (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda
 
Victor Moreno
Stock and Other Ownership Interests - ANILING
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; Novartis; Targos GmbH
Consulting or Advisory Role - Bayer; MSD Oncology; Targos GmbH
Travel, Accommodations, Expenses - Novartis